296 results about "Hepatic carcinoma" patented technology

The present invention relates to therapeutic protocols and pharmaceutical compositions designed to target HBx mediated activation of Src kinase, members of the Src tyrosine kinase family and components of the Src kinase family signal transduction pathways for the treatment of HBV infection and related disorders and diseases, such as HCC. The invention further relates to pharmaceutical compositions for the treatment of HBV infection targeted to HBx and its essential activities required to sustain HBV replication. The invention is based, in part, on the Applicants' discovery that activation of Src kinase signaling cascades play a fundamental role in mammalian hepadnavirus replication. Applicants have demonstrated that HBx mediates activation of the Src family of kinases and that this activation is a critical function provided by HBx for mammalian hepadnavirus replication.

The invention belongs to the technical field of gene engineering, and discloses sgRNA of targeting IGF-IR gene. The nucleotide sequence of the sgRNA of targeting IGF-IR gene is represented by SEQ ID NO:2. According to applications, a Crispr / cas9-sgRNA lentiviral vector system is adopted, knockout or modification of human hepatoma cell line IGF-IR gene on cellular level is realized successfully, hepatoma carcinoma cell IGF-IR gene transcriptional level is reduced obviously, hepatoma carcinoma cell proliferation, invasion, and migration capacities are reduced, a novel method is provided for treatment of hepatic carcinoma, and clinical application prospect is promising.

The invention provides preparation and application of an alpha fetoprotein and carcino-embryonic antigen electrochemiluminescence sensor, and belongs to the technical fields of nano function material, clinical analysis, a bioseneor technology and electrochemistry. The characteristics that platinum nanoparticle @meso-porous silicon @ graphene nanocomposite (PtNPs@m-Si@GS) is strong in conductivity, good in stability, large in specific surface area, good in biocompatibility, strong in catalytic activity and the like are utilized in preparation; an alpha fetoprotein second antibody (anti-alpha fetoprotein (AFP)) and a carcino-embryonic antigen secondary antibody (anti-carcino-embryonicantigen (CEA)) are marked, so as to prepare the marked second antibodies Ru-PtNPs@M-Si@GS / anti-AFP and luminol-PtNPs@M-Si@GS / anti-CEA; and the sensitivity of the sensor is obviously improved. Compared with other single-channel electrode sensors, alpha fetoprotein and carcino-embryonic antigen can be simultaneously detected on a same electrode at one time; the detection efficiency is obviously improved; and the alpha fetoprotein and carcino-embryonic antigen electrochemiluminescence sensor has important scientific significance and application value on clinical early diagnosis of hepatic carcinoma.

The present invention relates to therapeutic protocols and pharmaceutical compositions designed to target HBx mediated activation of Src kinase, members of the Src tyrosine kinase family and components of the Src kinase family signal transduction pathways for the treatment of HBV infection and related disorders and diseases, such as HCC. The invention further relates to pharmaceutical compositions for the treatment of HBV infection targeted to HBx and its essential activities required to sustain HBV replication. The invention is based, in part, on the Applicants' discovery that activation of Src kinase signaling cascades play a fundamental role in mammalian hepadnavirus replication. Applicants have demonstrated that HBx mediates activation of the Src family of kinases and that this activation is a critical function provided by HBx for mammalian hepadnavirus replication.

The invention belongs to the genetic engineering and tumour medicine fields and discloses an SNP marker related to primary hepatocellular carcinoma auxiliary diagnosis and an application of the SNP marker. The marker is a combination of rs7574865, rs1012068, rs17401966, rs2596542, rs455804, rs9272105, rs9275319 and rs9275572. The marker can be used for preparing a hepatic carcinoma auxiliary diagnosis kit.

The invention discloses a single-stranded deoxyribonucleic acid (ssDNA) aptamer targeting human highly metastatic hepatoma carcinoma cell and an application of the ssDNA aptamer, and relates to the field of diagnosis and treatment of the recurrence and metastasis of the hepatocellular carcinoma, so that the high-efficient novel specific molecules are provided for the diagnosis and treatment of the recurrence and metastasis of the hepatocellular carcinoma. According to the invention, a subtractive cell-SELEX technology is applied, two hepatoma carcinoma cell systems with same genetic background and obviously different metastatic potentials are a subtractive target and a screening target, respectively, and the hepatoma carcinoma cell systems are MHCC97-L (low metastasis) and HCCLM9 (high metastasis), so that the ssDNA aptamer is capable of specifically recognizing the highly metastatic potential hepatoma carcinoma cell HCCLM9. The aptamer is a single-stranded DNA molecular probe capableof specially combining with a surface of a human highly metastatic hepatoma carcinoma cell membrane, and a nucleotide sequence of aptamer is represented by SEQ ID No.1. The aptamer is expected to play an important role in preparation of a reagent for diagnosing or treating the hepatocellular carcinoma.

This invention provides a genetically tractable in situ non-human animal model for hepatocellular carcinoma. The model is useful, inter alia, in understanding the molecular mechanisms of liver cancer, in understanding the genetic alterations (e.g., in oncogenes and tumor suppressor genes) that lead to chemoresistance or poor prognosis, and in identifying and evaluating new therapies against hepatocellular carcinomas. The liver cancer model of this invention is made by altering hepatocytes to increase oncogene expression, to reduce tumor suppressor gene expression or both, preferably by inducible, reversible, and / or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene, and by transplanting the resulting hepatocytes into a recipient non-human animal. The invention further provides a method to treat cancer involving cooperative interactions between a tumor cell senescence program and the innate immune system.

The invention provides a mass spectrometry model used for detecting hepatocellular carcinoma serum characteristic protein, and a preparation method used for the mass spectrometry model. The method uses a plurality of characteristic protein combinations which are different in hepatocellular carcinoma patients and normal people to detects the hepatocellular carcinoma serum, adopts a method combining the traditional statistics with the modern biological informatics to process data, measures the protein combination spectrum spectrogram of serum samples of hepatocellular carcinoma patients and normal people by utilizing a mass spectrograph, and screens out the tumor markers of five corresponding hepatocellular carcinoma characteristic proteins, thus preparing the mass spectrometry model used for detecting the hepatocellular carcinoma serum characteristic proteins and provides foundation and resource for finding newer and more ideal tumor markers.

Leptin was previously demonstrated to exert potent immune modulatory properties in several immune mediated disorders. The aim of the study was to determine leptin's anti-tumor effect in a murine model of human hepatocellular carcinoma (HCC). In vivo, Athymic T cell deficient (nude) mice transplanted with 1×106 human Hep3B cells, followed by administration of two daily intraperitoneal doses of 0.5 mg / gram leptin for 6 weeks. Leptin administration induced a significant reduction in tumor size and improved survival in nude mice. Histologically, tumors of leptin-administered mice featured increased inflammatory exudate in interphase areas. Leptin-induced tumor suppression was associated with a significant increase in peripheral natural killer (NK) cell number. Splenocytes from leptin-treated mice featured decreased expression of CIS mRNA. To determine which lymphocyte subset is a prerequisite for the anti tumor effect of leptin, T&B cell deficient (Scid) mice and T,B& NK deficient (Scid-Beige) mice were subcutaneously implanted with Hep3B tumor cells, with and without the daily intraperitoneal administration of 0.5 mg / gram leptin for 6 weeks. SCID mice featured leptin-associated tumor suppression similar to those of nude mice. In contrast, NK-deficient SCID-Beige mice developed larger tumors. To further establish natural killer cell's central role in mediation of leptin's anti-tumor effect, NK cells were incubated in vitro with increasing doses of leptin, demonstrating a dose-dependent increase in cytotoxic activity. Incubation of leptin with hepatoma cell line was found to induce a dose-dependent reduction in hepatoma cell proliferation, suggesting an additive direct anti-tumor effect. Further synergism in inhibition of hepatoma cell proliferation in vitro was achieved following addition of natural killer cells. HCC cells expressed leptin receptor mRNA, while addition of leptin induced increased mRMA expression of STAT2 and SOCS1 on tumor cell lines. Leptin administration induces a significant suppression of human HCC. This effect is mediated by induction of natural killer cell proliferation and activation, and by direct inhibition of tumor growth. Decreased natural killer cell expression of inhibitory CIS protein and over expression of the anti-proliferative STAT2 and SOCS1 proteins in HCC lines may underline both anti cancerous effects of leptin.

The invention provides a hepatic carcinoma targeted photo-thermal therapeutic agent as well as a preparation method and an application thereof and belongs to the field of biomedical engineering. The hepatic carcinoma targeted photo-thermal therapeutic agent is prepared with the method comprising the following steps: (1) preparing biotinylation nanometer microbubbles; (2) preparing a Cy7 fluorescently-labeled biotinylation anti-GPC3 (glypican3) antibody; (3) preparing biotinylation RGO (reduced graphene oxide); (4) coupling the products prepared in the step (1), step (2) and step (3) through a biotin-avidin system to obtain the hepatic carcinoma targeted photo-thermal therapeutic agent. The hepatic carcinoma targeted photo-thermal therapeutic agent has ultrasonic and fluorescence imaging functions, mediates RGO targeted delivery with an ultrasound-targeted microbubble destruction technology, monitors a photo-thermal therapeutic process in real time, can be used for preparing drugs for hepatic carcinoma therapy and has excellent clinical application value.

The present invention is concerned with deuterium-enriched pyrimidine compounds of formula I, their derivatives, enantiomers, diastereomers, solvates and pharmaceutical salts thereof,and their uses in the treatment, prevention and modulation of various diseases including chronic liver diseases, liver cirrhosis, liver fibrosis, hepatocellular carcinoma, liver cancer, renal cell carcinoma, kidney cancer, colorectal cancer, brain cancer, breast cancer, blood cancer, lung cancer, thyroid cancer, ovarian cancer, pancreas cancer, prostate cancer, stomach cancer, testicular cancer, uterus cancer, intestinal cancer, skin cancer, and other forms of cancer, carcinoid tumors, teratocarcinoma, tumor progression, metastasis and fibrosis in the neuroendocrine neoplasia, fibrotic processes as well as a disease state modulated directly or indirectly with 5-HT receptors, 5-HT1, 5-HT1A, 5-HT2 receptors, 5-HT2A and 5-HT2B receptors, dopamine receptors and multiple kinase pathways.

According to the liver tumor automatic classification method and device based on multi-stage CT image analysis, full-automatic bile duct cell carcinoma and hepatocellular carcinoma can be recognized,and a high-precision bile duct cell carcinoma and hepatocellular carcinoma recognition model is obtained. The method comprises the following steps: (1) acquiring a contrast-enhanced abdominal CT scanning image, storing the contrast-enhanced abdominal CT scanning image as an arterial phase, a portal vein phase and a delay phase, and carrying out definite diagnosis on liver cancer categories to which all data belong to serve as a model training gold standard; (2) constructing a three-dimensional full convolutional neural network segmentation model, and segmenting the intrinsic characteristics ofthe liver tissue in each stage from the abdominal CT image through model training learning; (3) constructing a three-dimensional convolutional neural network classification model; and inputting the image data obtained by segmentation into a classification model for training, so as to enable the model to perform joint learning and training on the cancer features in multiple periods, thereby predicting the category to which the cancer belongs, comparing the prediction result with a gold standard, and supervising the training process of the model in a loss value feedback mode.

The invention relates to a quinoline multi-target kinase inhibitor with antitumor activity and a preparation method thereof. A general structural formula of the compound is shown in a formula (I) described in the specification. In vitro cell experiments verify that the compound provided by the invention has strong in vitro inhibitory activity on five common tumor cell lines, namely human thyroid carcinoma SW579, human hepatic carcinoma HepG2, human lung adenocarcinoma A549, human colorectal adenocarcinoma HCT116 and human gastric carcinoma MKN45, antitumor activities of most of target compounds are better than or equivalent to that of a positive control drug Cabozantinib, and the in vitro cell experiments verify that the compound provided by the invention has strong inhibitory activity on two kinases KDR and MET, so that the compound provided by the invention has a broad application prospect in preparation of a new antitumor drug.

The invention discloses a prepack eccentric column of fucosido-fucosyl Golgi protein 73 (or Golgi protein 73 heterogeneous body) relative to liver cancer separation, which is characterized by the following: comprising upper separator tube and lower collecting pipe; packing affinity agent of coupling small lentils agglutinine (LCA); assembling a filter cloth on the bottom of the upper separator tube; packing buffer solution in lower collecting pipe; binding small lentils agglutinine (LCA) and sugar chain fucosido-fucosyl Golgi protein 73; centrifuging through adding into eluent; proceeding purify Fuc-GP73 part. This invention discloses a chemoluminescence testing agent case with the eccentric column and enzyme joint immunoassay agent case with the column and preparing and using method. This agent case can test the content of liver cancer fucosido-fucosyl Golgi protein 73, which can provide support for early stage diagnosis.

Disclosed are pharmaceutical compositions and methods of treating hepatoma by administering to patients or other populations of cells agents that selectively inhibit the uptake of glutamine by hepatocarcinoma cells, causing the concomitant apoptosis of hepatocarcinoma cells. Preferred agents target the amino acid transporter B0 (ATB0) protein for inhibition. Disclosed are antisense polynucleotides that reduce the expression of ATB0 in hepatocarcinoma cells, causing those cells to reduce the uptake of glutamine and subsequently undergo selective apoptosis.

The invention discloses a construction method of a unified diagnosis-prognosis-recurrence model for patients with hepatocellular carcinoma. The method comprises the following steps: step 1) collectinggene expression data and DNA methylation data of hepatocellular carcinoma; step 2) analyzing the gene expression data and the DNA methylation data of the hepatocellular carcinoma, and identifying DNAmethylation driver genes in hepatocellular carcinoma; and step 3) establishing a diagnosis-prognosis-recurrence model for the patients with hepatocellular carcinoma through single-factor Cox regression, minimum absolute constriction and selection operator regression analysis and multi-factor Cox regression analysis on the DNA methylation driver genes in the hepatocellular carcinoma. The unified diagnosis-prognosis-recurrence model composed of the three DNA methylation driver genes is found and verified, so a novel research direction is provided for screening of hepatocellular carcinoma biomarkers, and new possibility is provided for individualized treatment of the patients with hepatocellular carcinoma.

The invention provides hepatocellular carcinoma-related klotho gene single-nucleotide polymorphism and its construction method and use. The hepatocellular carcinoma-related klotho gene single-nucleotide polymorphism and its construction method have the advantages that 1, through a detection method provided by the invention, polymorphism of a single nucleotide located in an exon 4 area of a human klotho gene can be detected fast and simply and it is diagnosed that if an individual has susceptibility of hepatocellular carcinoma so that the hepatocellular carcinoma-susceptible population screening and hepatocellular carcinoma prevention are promoted; 2, a T allele point of rs648202 is used as a drug design target point for drug screening so that an active molecule adjusting a klotho gene expression level is selected and development of a novel antitumor drug is promoted; 3, through primer sequences and HaeIII endonuclease provided by the invention, simple, efficient and specific detection of rs648202 polymorphism is realized; and 4, according to hepatocellular carcinoma-related klotho gene single-nucleotide polymorphism, a hepatocellular carcinoma genetic diagnosis kit can be constructed.

The invention provides establishment and application of a hepatocellular carcinoma cell line HCC-LY10. Specifically, the hepatocellular carcinoma cell line HCC-LY10 provided in the invention has stable traits, can be subcultured stably and repeatedly, and is applicable to established animal models of hepatocellular carcinoma, thus being an ideal cell line for the basic and preclinical phase application study of hepatocellular carcinoma. In addition, the hepatocellular carcinoma cell line HCC-LY10 partially expresses hepatocellular carcinoma stem cell marker EpCAM. The invention also provides application of the cell line in establishing model animals, screening drugs, and other aspects.

The invention belongs to the technical field of biomedicine, and specifically discloses an application of m5C methylation-related regulatory genes in prognosis prediction of hepatocellular carcinoma.The m5C methylation-related regulatory genes include a NSUN4 gene and an ALYREF gene, and reagents for detecting the expression levels of the NSUN4 gene and the ALYREF gene can be used to prepare prognostic prediction products of the hepatocellular carcinoma. By detecting the expression levels of the NSUN4 gene and the ALYREF gene, the survival time of hepatocellular carcinoma patients can be effectively distinguished, so that a novel way is provided for the prognosis prediction of the hepatocellular carcinoma, and a reference basis is provided for a clinician to analyze the condition of the hepatocellular carcinoma.

The invention discloses a cell electrochemical sensor for analyzing joint toxicity of fungaltoxin, belonging to the fields of analysis and detection of food quality. According to the cell electrochemical sensor, the sensitivity of the sensor is increased by virtue of electroplating gold nanoparticles, an in-vivo physiological living environment of cells is simulated by virtue of laminin, and a three-dimensional model is constructed by virtue of rat tail collagens so as to relatively truly reappear cell morphology; and the constructed cell electrochemical sensor can rapidly and sensitively respond to the influences caused by the fungaltoxin to human hepatoma carcinoma cells, equipment is convenient and rapid and low in production cost, and by combining with an electrochemical resistance value and a joint index method, the type and degree of a joint action of the fungaltoxin can be rapidly judged. The constructed portable cell electrochemical sensor is successfully applied to the toxicity analysis of the fungaltoxin in foods and has good application prospects in the analysis of the joint toxicity of the fungaltoxin.

The invention discloses an agent plate for testing hepatocarcinoma and a preparation method and the application thereof. The agent plate is composed of a rigid plate and an agent strip attached to the rigid plate, and the agent strip is formed by sequentially and closely splicing absorbent filter paper, a pyroxylin membrane, a glass fibre membrane and a sample adsorption glass fibre membrane from top to bottom, wherein a gold-labeled anti-mouse AFP monoclonal antibody is absorbed by the glass fibre membrane; an agglutinin coated detection line is arranged at one end of the pyroxylin membrane, which is adjacent to the glass fibre membrane, and a goat anti mouse IgG coated contrast line is arranged at the other end which is adjacent to the absorbent filter paper; and the lower end of the sample adsorption glass fibre membrane is provided with a row of loading holes. The agent plate for testing hepatocarcinoma has the advantages that a fluorescence microscope, an Elisa tester and other expensive instruments are not needed, and the agent plate is much more suitable for field test; the agent plate is safer since radioactive isotopes, TMB and other harmful substances or chemical substances are not needed in testing processes; test results can be preserved for a long time; and the operation of the agent plate is easy and fast, and the agent plate can be operated by a single person.

The invention provides a GP73 antigen silicon-based magnetic bead conjugate as well as a competition method GP73 quantitative determination kit formed by taking the conjugate as one of the components and matching with other components. The kit disclosed by the invention consists of a Golgi protein 73 (GP73) antigen silicon-based magnetic bead conjugate working solution, a Golgi protein 73 (GP73) calibration material, an alkaline phosphatase labeled Golgi protein 73 (GP73) monoclonal antibody working solution, a cleaning solution and a chemiluminescence substrate. Meanwhile, the invention provides a method for preparing the GP73 antigen silicon-based magnetic bead conjugate and a method for preparing each component in the kit. The method comprises the following steps: preparing the GP73 antigen silicon-based magnetic bead conjugate working solution, preparing an enzyme-labeled antibody, preparing the calibration material, preparing the cleaning solution and preparing the chemiluminescence substrate. The kit provided by the invention can be mainly applied to diagnosis of primary hepatic carcinoma and has the advantages of high sensitivity, wide linear range, hook effect avoidance, low cost, short detection time consumption and the like.

The invention provides a Chinese medicament for treating disseminated hepatic carcinoma, wherein the recipe includes astragalus root 15g, root of red rooted saliva 10g, pseudostellaria root 15g, white atractylodes rhizome 10g, poria cocos, tortoise shell, turtle shell each 15g, burred tuber, zedoary each 10g, oriental wormwood, bupleurum root each 15g, haw, medicated leaven, malt 10g, oriental water plantain rhizome 15g, oldenlandia 30g, honey-fried licorice root 10g. The medicament is prepared through conventional processes with easy accessibility of raw materials, simplified formulation and preparing procedures, and low cost of medicament production.

The invention provides application of polyguluronate sulfate to anti-hepatitis B virus medicine preparation. Experiments prove that the polyguluronate sulfate is capable of well inhibiting expression of an HBV (hepatitis B virus) HBsAg (hepatitis B surface antigen) and an HBV HBeAg (hepatitis Be antigen) in a hepatocellular carcinoma cell line HepG2.2.15, remarkably inhibiting expression of HBV-S mRNA (messenger ribonucleic acid) in the hepatocellular carcinoma cell line HepG2.2.15, enhancing generation and secretion of anti-virus immunity-associated IFN (interferon)-beta in cells and activating NF (nuclear factor)-kappa B and MAPK (mitogen-activated protein kinase) signal pathways. The polyguluronate sulfate which is a marine sulfated polysaccharide compound has the advantages of rich resources, low cost, high safety and the like, and is obviously superior to positive control drug lamivudine in anti-HBV effect, thereby being promising in application prospect of anti-hepatitis B virus medicine preparation.

The invention discloses an alpha-pinene extracted from pine needle, its extraction method and application for resisting tumor. The alpha-pinene of the invention is extracted from pine needle. It is proved by experiments that alpha-pinene has an obvious inhibition effect on the proliferation of hepatoma carcinoma cell. Therefore, the alpha-pinene of the invention can be used in the preparation of drugs for treating tumor related diseases and has great significance.

The invention provides a medicament for treating cancer, which is a pure natural Chinese medicinal herb preparation with good effect for treating lung carcinoma, hepatic carcinoma, gastric carcinoma, restocarcinoma and breast cancer.

The invention discloses a long noncoding RNA (lncRNA) marker associated with hepatocellular carcinoma as well as a detection primer and application thereof. The lncRNA marker associated with hepatocellular carcinoma is RP11-284F21.10. By performing high throughput sequencing, significant up-regulation of RP11-284F21.10 expression in patients with hepatocellular carcinoma is discovered for the first time by the invention; moreover, up-regulation of RP11-284F21.10 expression in patients with hepatocellular carcinoma is further verified by performing QPCR, suggesting that the RP11-284F21.10 can be used as a biomarker in diagnosis and treatment of hepatocellular carcinoma.

The invention relates to a combined diagnostic marker for inflammation-associated HCC and an application thereof. Combined application of an STK4 protein in a peripheral blood monocyte or plasma, phosphorylated p65 (p-p65) and phosphorylated STAT3 (p-STAT3) in the peripheral blood monocyte and an IL-6 protein in the plasma as the marker for inflammation-associated HCC is provided for the first time, and a theoretical basis and a simpler detection method are provided for fast and early diagnosis and monitoring of HCC.

The invention discloses a polyethylene glycol modified glycyrrhetinic acid and curcumin compound used for resisting hepatic carcinoma, and a preparation method thereof. The preparation method comprises the following steps: (1), the preparation of methoxy polyethylene glycol-tosylate (mPEG-OTs); (2), the preparation of methoxy polyethylene glycol-phthalimide (mPEG-PI); (3), the preparation of single-ended amino methoxy polyethylene glycol (mPEG-NH2); (4), the preparation of methoxy polyethylene glycol-glycyrrhetinic acid (mPEG-18beta-GA); (5), the preparation of polyethylene glycol modified glycyrrhetinic acid and curcumin compound (mPEG-GA and CUR compound), wherein the yield of the mPEG-OTs can reach 84.54 percent or above, the yield of the mPEG-PI can reach 88.96 percent or above, the yield of the mPEG-NH2 can reach 88.72 percent or above, and the yield of the mPEG-18beta-GA can reach 82.43 percent or above. The purity of the mPEG-OTs can reach 95.74 percent or above, the purity of the mPEG-PI can reach 96.88 percent or above, the purity of the mPEG-NH2 can reach 99.51 percent or above, the purity of the mPEG-18beta-GA can reach 99.65 percent or above, the yield of the mPEG-GA and the CUR compound can reach 83.31 percent or above, and the purity of the mPEG-GA and the CUR compound can reach 99.78 percent or above.